OncoPharm
By John Bossaer
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by John Bossaer
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 11
Reviews: 0
Episodes: 407
Description
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
| Episode | Date |
|---|---|
|
ASH 2025
|
Dec 11, 2025 |
|
DPYD Deficiency Testing
|
Dec 04, 2025 |
|
Cornucopia of Autumn Updates
|
Nov 26, 2025 |
|
PGYNone: Dandelion Effect
|
Nov 20, 2025 |
|
PGY1 Pathway: Road Trip!
|
Nov 13, 2025 |
|
PGY2 Pathway: A Planned City
|
Nov 06, 2025 |
|
Tale from the Crypt: Belantamab Mafodotin
|
Oct 30, 2025 |
|
ESMO 2025
|
Oct 23, 2025 |
|
IL-2
|
Oct 16, 2025 |
|
Maintenance Therapy in Small Cell Lung Cancer
|
Oct 09, 2025 |
|
PARAMOUNT - Maintenance Pemetrexed
|
Oct 03, 2025 |
|
SC Pembro, Biotin, 5-yr POLARIX data
|
Sep 25, 2025 |
|
ALASCCA
|
Sep 21, 2025 |
|
EGFRm NSCLC Updates
|
Sep 11, 2025 |
|
Time to Cilta-Cel-ebrate?
|
Sep 04, 2025 |
|
RNA Vaccine Potential as a Cancer Treatment
|
Aug 28, 2025 |
|
Venetoclax Dosing & APOLLO
|
Aug 21, 2025 |
|
Zongertinib
|
Aug 14, 2025 |
|
Dordaviprone & RCT to prevent ADRs
|
Aug 07, 2025 |
|
ProMACE-CytaBOM
|
Jul 31, 2025 |
|
Testicular Cancer in a Nutshell
|
Jul 17, 2025 |
|
Supportive Care Updates
|
Jul 10, 2025 |
|
Linvoseltamab & sunvozertinib
|
Jul 03, 2025 |
|
Antiandrogen Withdrawal
|
Jun 25, 2025 |
|
June 2025 Updates
|
Jun 19, 2025 |
|
ASCO 2025
|
Jun 05, 2025 |
|
CLEOPATRA
|
May 29, 2025 |
|
Talking about cancer misinformation
|
May 22, 2025 |
|
Four New Drugs
|
May 22, 2025 |
|
Mg to Prevent Cisplatin Kidney Injury
|
May 08, 2025 |
|
TI-CH, Updates on dostarlimab, ventoclax, & zongertinib
|
May 01, 2025 |
|
BRCA Reversion Mutations
|
Apr 24, 2025 |
|
HOPA 25 Recap
|
Apr 17, 2025 |
|
Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
|
Apr 08, 2025 |
|
API-CAT & IMPROVE
|
Apr 03, 2025 |
|
Topotecan
|
Apr 03, 2025 |
|
Keynote 811 Update
|
Mar 19, 2025 |
|
Polar: Cryotherapy or Compression to Prevent Taxane-induced neuropathy
|
Mar 13, 2025 |
|
About Herb Drug Interactions
|
Mar 06, 2025 |
|
Rethinking Premeds
|
Feb 27, 2025 |
|
AMPLIFY
|
Feb 20, 2025 |
|
OncoPharm M & M: Fatal TLS & Fatal T-cell lymphoma post-CAR-T
|
Feb 13, 2025 |
|
[Re-release] Rituximab
|
Feb 06, 2025 |
|
Acalabrutinb + BR and sotorasib + panitumumab
|
Jan 30, 2025 |
|
Datoptamab deruxtecan
|
Jan 22, 2025 |
|
Dex Dosing in MM, Tec-Tal, & postMONARCH
|
Jan 16, 2025 |
|
Breakwater, Ensartinib, & SC Nivo
|
Jan 09, 2025 |
|
The Accelerated Approval Pathway
|
Jan 02, 2025 |
|
2024 New Drug Review
|
Dec 19, 2024 |
|
A Feast Of Updates
|
Dec 12, 2024 |
|
Zenocutuzumab
|
Dec 05, 2024 |
|
Revumenib
|
Nov 21, 2024 |
|
Anthracycline Use In Breast Cancer
|
Nov 14, 2024 |
|
SWISH
|
Nov 07, 2024 |
|
Zolbetuximab
|
Oct 31, 2024 |
|
S1826 & INTERLACE
|
Oct 24, 2024 |
|
Inavolisib
|
Oct 17, 2024 |
|
Autumnal (2024) AML Updates
|
Oct 10, 2024 |
|
MSI-High Rectal Cancer Treatment
|
Oct 03, 2024 |
|
NATALEE + a slew of FDA updates
|
Sep 26, 2024 |
|
ESMO 2024
|
Sep 19, 2024 |
|
Doxorubicin + Trabectedin
|
Sep 05, 2024 |
|
Chapter 1. Doses Matter
|
Aug 29, 2024 |
|
Cross-Trial Comparison Don'ts
|
Aug 22, 2024 |
|
Olanzapine For MEC
|
Aug 15, 2024 |
|
Afamitresgene Autoleucel & Vorasidenib
|
Aug 08, 2024 |
|
Perioperative ICI Trial Design & Blood Test Screening For Colorectal Cancer
|
Jul 31, 2024 |
|
The Auto Transplant Breast Cancer Scandal
|
Jul 25, 2024 |
|
Vacation Reflections
|
Jul 18, 2024 |
|
June '24 Updates & ATOPP Travelogue
|
Jul 03, 2024 |
|
MARIPOSA
|
Jun 27, 2024 |
|
ViPOR
|
Jun 21, 2024 |
|
Imetelstat, Targeting Telomerase
|
Jun 13, 2024 |
|
ASCO 2024
|
Jun 06, 2024 |
|
Updated ASCO-ONS Antineoplastic Safety Standards
|
May 30, 2024 |
|
Tarlatamab
|
May 23, 2024 |
|
QT Prolongation In Oncology
|
May 16, 2024 |
|
Pro-MACE-CytaBOM
|
May 09, 2024 |
|
Tisotumab Vedotin, HD Mtx In CNS Lymphoma & Class III BRAF Mutations
|
May 02, 2024 |
|
Late April Updates
|
Apr 25, 2024 |
|
NSCLC In A Nutshell
|
Apr 19, 2024 |
|
HOPA '24, Site Agnositc T-DXd, & ALINA
|
Apr 11, 2024 |
|
Tumor Lysis Syndrome
|
Apr 04, 2024 |
|
Updates In RCC, Pancreatic Cancer, And Skin Cancer In SOT
|
Mar 28, 2024 |
|
Colon Cancer Screening Wars
|
Mar 14, 2024 |
|
Bladder Cancer Updates
|
Mar 07, 2024 |
|
SPARED & D-TORCH
|
Feb 29, 2024 |
|
Lifileucel & FLAURA2 Updates
|
Feb 22, 2024 |
|
NAPOLI 3, POUT, & Ivosidenib - Azole DDIs
|
Feb 15, 2024 |
|
Small Cell Carcinoma, Prostate Edition
|
Feb 08, 2024 |
|
Rethinking Some Fundamental Considerations
|
Feb 01, 2024 |
|
Jan 2024 Updates...
|
Jan 25, 2024 |
|
Development Of Generic Lenalidomide with Dr. Ryan Beechinor
|
Jan 10, 2024 |
|
Lenalidomide
|
Jan 04, 2024 |
|
2023 New Drug Review
|
Dec 21, 2023 |
|
ASH23 Appetizers
|
Dec 14, 2023 |
|
VISTA
|
Dec 07, 2023 |
|
Gamma Secretase Inhibition et al
|
Nov 30, 2023 |
|
Repotrectinib & Capivasertib
|
Nov 23, 2023 |
|
Fruquintinib And Osimertinib-Chemo in Combo?
|
Nov 16, 2023 |
|
Elderly AML & Burkitt Lymphoma Updates
|
Nov 09, 2023 |
|
Landmarks Of Stage III NSCLC
|
Nov 02, 2023 |
|
ESMO 2023
|
Oct 26, 2023 |
|
Enzalutamide monotherapy? Plus, nivolumab & pembrolizumab approval updates
|
Oct 19, 2023 |
|
BRAF V600E Updates
|
Oct 12, 2023 |
|
Press Release Updates
|
Oct 05, 2023 |
|
Imatinib [Re-release]
|
Sep 28, 2023 |
|
Carboplatin Paclitaxel in Ovarian Cancer
|
Sep 21, 2023 |
|
HER3-DXd & Motixafortide
|
Sep 14, 2023 |
|
RECISTance Is Futile
|
Sep 07, 2023 |
|
DPYD Variant Dosing & ICIs In Pancreatic Cancer
|
Aug 31, 2023 |
|
Nab-Paclitaxel
|
Aug 24, 2023 |
|
Niraparib + Abiraterone, Elranatamab, & Melphalan Updates
|
Aug 17, 2023 |
|
Talquetamab & STOP-CA
|
Aug 10, 2023 |
|
Ruby Trial & Quizartinib Toxicity
|
Aug 03, 2023 |
|
BCOP Study Tips
|
Jul 27, 2023 |
|
Chemotherapy Sequencing In Colorectal Cancer
|
Jul 20, 2023 |
|
Phase 1 Clinical Trials In Oncology with Dr. Donald Harvey
|
Jul 13, 2023 |
|
Investigational Drug Services In Oncology with Dr. Jackie Saunders
|
Jul 06, 2023 |
|
NADIM II & Favorable Risk RCC
|
Jun 29, 2023 |
|
Glofitamab & TALAPRO - 2
|
Jun 22, 2023 |
|
ASCO '23 Entrees
|
Jun 15, 2023 |
|
ASCO '23 Appetizers
|
Jun 08, 2023 |
|
PROpel and Cilostazol to Prevent Paclitaxel Neuropathy
|
Jun 01, 2023 |
|
Epcoritamab
|
May 25, 2023 |
|
Trimodality Treatment For Bladder Cancer
|
May 18, 2023 |
|
GAIA-CLL13 & COSMIC-313
|
May 11, 2023 |
|
SUNLIGHT
|
May 04, 2023 |
|
QuANTUM First (Quizartinib 1st Line in AML)
|
Apr 27, 2023 |
|
ICI + Bacterial Supplementation
|
Apr 20, 2023 |
|
Neoadjuvant Chemo In Breast Cancer
|
Apr 13, 2023 |
|
Olanzapine & Pembrolizumab (endometrial, urothelial) Updates
|
Apr 06, 2023 |
|
[Re-release] Tales of Brave Iressa (2017)
|
Mar 30, 2023 |
|
Linezolid vs. Vanc In Neutropenic Fever
|
Mar 23, 2023 |
|
Chemo-Induced Ovarian Dysfunction
|
Mar 16, 2023 |
|
S1801 (Neoadjuvant Pembro In Melanoma)
|
Mar 09, 2023 |
|
DA-EPOCH (R)
|
Mar 02, 2023 |
|
Cannabis Use With ICIs
|
Feb 24, 2023 |
|
Instant KarMMa
|
Feb 16, 2023 |
|
CodeBreak200 And Elderly AML Survival
|
Feb 09, 2023 |
|
Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
|
Feb 02, 2023 |
|
HER2 Targeting Era Of Colorectal Cancer Begins
|
Jan 26, 2023 |
|
Adjuvant Interferon In Melanoma
|
Jan 19, 2023 |
|
Breast Cancer In A Nutshell
|
Jan 12, 2023 |
|
Mosunetuzumab And Same-day Pegfilgrastim w/ ddAC
|
Jan 05, 2023 |
|
2022 New Drug Review
|
Dec 29, 2022 |
|
Project Renewal: Capecitabine
|
Dec 22, 2022 |
|
ASH 2022 Highlights
|
Dec 16, 2022 |
|
TILs, Olutasidenib, T-DXd
|
Dec 08, 2022 |
|
Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication
|
Dec 01, 2022 |
|
Mirvetuximab Soravtansine
|
Nov 17, 2022 |
|
Metastatic NSCLC Updates: Role of CTLA-4 inhibitors?
|
Nov 10, 2022 |
|
No Room for MABs at the INN
|
Nov 03, 2022 |
|
Tremelimumab & Teclistamab
|
Oct 27, 2022 |
|
Pemetrexed Maintenance
|
Oct 20, 2022 |
|
Allo CAR-T & Aprepitant For EGFR TKI Pruritis
|
Oct 13, 2022 |
|
Futibatinib, ESR1, & GPRC5D
|
Oct 06, 2022 |
|
Thiosulfate And Selpercatinib
|
Sep 29, 2022 |
|
9 22
|
Sep 22, 2022 |
|
ESMO 2022 - NICHE-2 and Codebreak 200
|
Sep 15, 2022 |
|
Biliary Tract Cancer & Pemigatinib (unrelated) Updates
|
Sep 09, 2022 |
|
Temozolomide + RT For GBM
|
Sep 01, 2022 |
|
All About Asparaginase
|
Aug 25, 2022 |
|
HER2 Mutated NSCLC
|
Aug 18, 2022 |
|
Updated Adjuvant Atezolizumab Data (& more)
|
Aug 11, 2022 |
|
The Infamous Erlotinib Study
|
Aug 04, 2022 |
|
Long Term Follow-Up
|
Jul 28, 2022 |
|
Living With Lupus
|
Jul 14, 2022 |
|
ICIs & PPIs - Something to Worry About?
|
Jul 07, 2022 |
|
APAP + ICI: An emerging concern?
|
Jun 30, 2022 |
|
FN Updates
|
Jun 23, 2022 |
|
LGBTQ Clinical Pearls
|
Jun 16, 2022 |
|
ASCO 2022 Highlights
|
Jun 09, 2022 |
|
Transgender Cancer Screening
|
Jun 02, 2022 |
|
What's Next In NSCLC & AML?
|
May 26, 2022 |
|
How To Use Our Favorite Guidelines
|
May 19, 2022 |
|
Docetaxel
|
May 12, 2022 |
|
Adjuvant HD Cisplatin-RT For High Risk Head & Neck Cancer
|
May 05, 2022 |
|
Melanoma In A Nutshell
|
Apr 28, 2022 |
|
Loong TFRs In CML, A Lack Of Agility, & CHEKCMATE 816
|
Apr 21, 2022 |
|
Ribociclib-Tamoxifen: A Cautionary Tale
|
Apr 14, 2022 |
|
Relatlimab + Nivo And the VISION trial
|
Apr 07, 2022 |
|
HOPA Boston Preview
|
Mar 28, 2022 |
|
DESTINY-Breast03
|
Mar 24, 2022 |
|
Chemo Toxicity Prediction & Risk
|
Mar 17, 2022 |
|
Neoadjuvant ddMVAC (bladder) & Nivo + Chemo (NSCLC)
|
Mar 10, 2022 |
|
7 + 3
|
Mar 03, 2022 |
|
Prostate Ca Updates From ASCO GU 22
|
Feb 24, 2022 |
|
Bacillus Calmette-Guerin
|
Feb 17, 2022 |
|
KIR, HLA - C, & Rituximab
|
Feb 10, 2022 |
|
GI Cancer Updates & Tebentafusp
|
Feb 03, 2022 |
|
Precision Medicine Demystified
|
Jan 27, 2022 |
|
New Hallmarks Of Cancers & LenPembro For Endometrial Cancer
|
Jan 20, 2022 |
|
Carfilzomib
|
Jan 13, 2022 |
|
So, You Want to Work (from home) as a Specialty Pharmacist
|
Jan 06, 2022 |
|
Drugs of 2021: Keep, Return Or Re-gift?
|
Dec 23, 2021 |
|
ASH21 The More Things Change...
|
Dec 16, 2021 |
|
So, You Want to be a Pediatric Oncology Pharmacist
|
Dec 09, 2021 |
|
Dasatinib Dosing & DREAMseq
|
Dec 02, 2021 |
|
Sun's Out, T Cells Out
|
Nov 18, 2021 |
|
So, You Want To Be An MSL Oncology Pharmacist
|
Nov 11, 2021 |
|
Asciminib
|
Nov 04, 2021 |
|
Adjuvant Atezo, Palbo-PPI Interaction? And More
|
Oct 28, 2021 |
|
Decreased Cardiotoxicity With Infusional Doxorubicin
|
Oct 21, 2021 |
|
Adjuvant Abemaciclib
|
Oct 14, 2021 |
|
Same Day Pegfilgrastim
|
Oct 07, 2021 |
|
Sarcomas In A Nutshell
|
Sep 30, 2021 |
|
ESMO21 & New Drugs (Cervical Ca Focus)
|
Sep 23, 2021 |
|
CASSIOPEIA Part 2
|
Sep 16, 2021 |
|
MMF For ITP
|
Sep 09, 2021 |
|
Hypercalcemia Of Malignancy (in Under 10)
|
Sep 02, 2021 |
|
Belzutifan and Recent Updates
|
Aug 26, 2021 |
|
Booster COVID-19 Vaccinations in Immunocompromised Patients
|
Aug 19, 2021 |
|
Sneaky TKI Toxicities
|
Aug 12, 2021 |
|
Acala V. Ibrutinib(again) & VidazaAllo
|
Aug 05, 2021 |
|
Breast Cancer & cGVHD Updates
|
Jul 29, 2021 |
|
GOG-172 (IP chemotherapy in ovarian cancer)
|
Jul 22, 2021 |
|
Advertising Amateur Hour
|
Jul 15, 2021 |
|
Capecitabine
|
Jul 08, 2021 |
|
Hormonal Toxicity Management In Breast Cancer Pts
|
Jul 01, 2021 |
|
EA1131 & TOURMALINE
|
Jun 24, 2021 |
|
Why Learning Oncology Is Hard
|
Jun 18, 2021 |
|
ASCO 2021
|
Jun 10, 2021 |
|
Sotorasib, Infigratinib, And More
|
Jun 03, 2021 |
|
Amivantamab
|
May 27, 2021 |
|
Venetoclax (with Dr. Kayleigh Marx)
|
May 20, 2021 |
|
Dosing In Obesity
|
May 13, 2021 |
|
Dostarlimab, Loncastuximab tesirine, & HER2 GI Updates
|
May 06, 2021 |
|
A Landmark Trial (without an FDA approval)
|
Apr 29, 2021 |
|
COVID Vaccine (Myeloma & CLL), MANHATTAN And More
|
Apr 22, 2021 |
|
IO Uh Oh
|
Apr 15, 2021 |
|
Cancer COVID Vaccine Updates + AMBORO
|
Apr 08, 2021 |
|
ICIs In Esophageal & GEJ Cancers
|
Apr 01, 2021 |
|
Emend's Emergence
|
Mar 25, 2021 |
|
Tivozanib (and More)
|
Mar 18, 2021 |
|
Indolent Lymphoma Week
|
Mar 12, 2021 |
|
Melphalan Flufenamide
|
Mar 04, 2021 |
|
Trilaciclib, Cemiplimab & GU Updates
|
Feb 25, 2021 |
|
Filgrastim Turns 30
|
Feb 18, 2021 |
|
Umbralisib
|
Feb 11, 2021 |
|
Tepotinib
|
Feb 04, 2021 |
|
Updates on mRCC and COVID-19 Vaccination
|
Jan 28, 2021 |
|
Updates T-DXd (gastric) & SC Dara (AL Amyloidosis)
|
Jan 21, 2021 |
|
JBR10
|
Jan 14, 2021 |
|
Updates from December 2020
|
Jan 07, 2021 |
|
Trastuzumab
|
Dec 31, 2020 |
|
Best Of 2020
|
Dec 23, 2020 |
|
COVID Vaccines In Cancer Patients - What We Don't Know
|
Dec 17, 2020 |
|
Breast Cancer Updates Dec. 2020
|
Dec 11, 2020 |
|
Colon Cancer Updates (IDEA & Keynote - 177)
|
Dec 03, 2020 |
|
CLOT
|
Nov 24, 2020 |
|
Pembrolizumab for TNBC & CML Updates
|
Nov 19, 2020 |
|
Ifosfamide
|
Nov 12, 2020 |
|
BELLINI
|
Nov 05, 2020 |
|
Updates On Keynote-426, Ph+ ALL, & Post - AlloHSCT Maintenance
|
Oct 29, 2020 |
|
Monthly Immunotherapy Expanded Approvals Update
|
Oct 21, 2020 |
|
Fulvestrant's Fumbled Dosing
|
Oct 15, 2020 |
|
Dexamethasone
|
Oct 08, 2020 |
|
IMpower 110 & Checkmate 153
|
Oct 01, 2020 |
|
ESMO 2020 & Beyond
|
Sep 24, 2020 |
|
TAX 327
|
Sep 17, 2020 |
|
Pralsetinib
|
Sep 11, 2020 |
|
BROCADE3
|
Sep 03, 2020 |
|
Alopecia
|
Aug 27, 2020 |
|
ATAC
|
Aug 20, 2020 |
|
VIALE-A (venetoclax + azacitidine for elderly/unfit AML)
|
Aug 13, 2020 |
|
New Anti-CD-19 And BCMA Options
|
Aug 06, 2020 |
|
Gemcitabine
|
Jul 30, 2020 |
|
Antiemetic & CIPN Guideline Updates
|
Jul 23, 2020 |
|
Conversation With A Breast Cancer Survivor
|
Jul 16, 2020 |
|
Neutropenic Fever 101
|
Jul 09, 2020 |
|
Early July FDA Updates
|
Jul 02, 2020 |
|
Clinical Trial Endpoints in Oncology
|
Jun 25, 2020 |
|
Lurbinectedin et al
|
Jun 18, 2020 |
|
LD Vs Ld
|
Jun 11, 2020 |
|
ASCO 2020
|
Jun 04, 2020 |
|
More NSCLC Updates (Checkmate-9La & ALTA-1L)
|
May 28, 2020 |
|
New Chemo - Free Immunotherapy Options For NSCLC
|
May 21, 2020 |
|
Selpercatinib & More!
|
May 14, 2020 |
|
Capmatinib & SC Daratumumab
|
May 08, 2020 |
|
Q 6 Pembro, PARP Inhibitors, MonarcHER, Griffin
|
Apr 30, 2020 |
|
Sacituzumab Govitecan, Tucatinib, And More!
|
Apr 24, 2020 |
|
Journal Club: Unscheduled Hydration in Patients Receiving HEC
|
Apr 16, 2020 |
|
Bevacizumab's Wild Ride For Metastatic Breast Cancer
|
Apr 09, 2020 |
|
Caravaggio
|
Apr 02, 2020 |
|
Bleomycin
|
Mar 27, 2020 |
|
Recent Landmarks (CLEOPATRA, Keynote189)
|
Mar 19, 2020 |
|
*Covid19 And Chemo*
|
Mar 16, 2020 |
|
Viz-Aflibercept Pricing: A Case Study
|
Mar 12, 2020 |
|
Pre - HOPA News Dunp
|
Mar 05, 2020 |
|
CYP2D6 & Tamoxifen Updates
|
Feb 27, 2020 |
|
CAR - NK
|
Feb 13, 2020 |
|
NK - 1 Antagonist Drug Interactions
|
Feb 06, 2020 |
|
Tazemetostat
|
Jan 30, 2020 |
|
Bendamustine
|
Jan 23, 2020 |
|
Avapritinib
|
Jan 16, 2020 |
|
Safety Signals & 6 - MP Hepatotoxicity
|
Jan 09, 2020 |
|
Trastuzumab Deruxtecan
|
Jan 02, 2020 |
|
Enfortumab-vedotin (& Asciminib)
|
Dec 26, 2019 |
|
Arsenic Sauce
|
Dec 19, 2019 |
|
ASH '19 Updates
|
Dec 12, 2019 |
|
Dose Dense AC
|
Dec 05, 2019 |
|
Cornucopia Of OncoPharm Updates
|
Nov 27, 2019 |
|
Zanubrutinib
|
Nov 21, 2019 |
|
Immunotherapy Interactions
|
Nov 14, 2019 |
|
Data Dive Into NK-1 Antagonists & Carboplatin
|
Nov 07, 2019 |
|
Carboplatin
|
Oct 31, 2019 |
|
ADAM VTE & Ibrutinib CV Toxicity
|
Oct 24, 2019 |
|
To Rechallenge, Or Not To Rechallenge
|
Oct 17, 2019 |
|
CASPIAN
|
Oct 10, 2019 |
|
ESMO 2019
|
Oct 03, 2019 |
|
Danorubicin 90 mg/m2 (AML induction)
|
Sep 24, 2019 |
|
New FDA approved indications for lenvatinib, pembro, and apalutamide
|
Sep 19, 2019 |
|
Curious Case Of Ibrutinib On Netflix
|
Sep 12, 2019 |
|
OncoPharm M & M Extreme Toxicity & Pharmacogenetics
|
Sep 05, 2019 |
|
Irinotecan
|
Aug 29, 2019 |
|
Entrectinib & Fedratinib
|
Aug 22, 2019 |
|
E1912: Ibrutinib/rituximab vs. FCR in CLL
|
Aug 15, 2019 |
|
ASCO VTE Guidelines (& more!)
|
Aug 08, 2019 |
|
Darolutamide
|
Jul 31, 2019 |
|
AC - - > T (q week)
|
Jul 25, 2019 |
|
Selinexor
|
Jul 18, 2019 |
|
Pain Management In Cancer
|
Jul 11, 2019 |
|
Tamoxifen
|
Jul 03, 2019 |
|
Ask OncoPharm: Advice for PGY2 Oncology Pharmacy Residents
|
Jun 27, 2019 |
|
Pembrolizumab Nets 2 More Approvals
|
Jun 20, 2019 |
|
Polatuzumab-vedotin
|
Jun 13, 2019 |
|
ASCO '19
|
Jun 06, 2019 |
|
Alpelisib
|
May 30, 2019 |
|
AC - - > T (q 3 week)
|
May 23, 2019 |
|
AC (NSABP B-15)
|
May 23, 2019 |
|
May Approvals, More Questions
|
May 16, 2019 |
|
Imatinib
|
May 09, 2019 |
|
Updates: bb2121 (myeloma CAR-T) and 1st line use of ivosidenib in AML
|
May 02, 2019 |
|
Lenvatinib vs. Sorafenib (HCC)
|
Apr 24, 2019 |
|
Erdafitinib
|
Apr 18, 2019 |
|
HOPA '19 Reflections
|
Apr 11, 2019 |
|
OncoPharm M & M - Drug Interaction
|
Apr 02, 2019 |
|
Etoposide
|
Mar 28, 2019 |
|
Updates: Venetoclax use in multiple myeloma, atezolizumab in small cell lung cancer
|
Mar 21, 2019 |
|
Metastatic Pancreatic CAncer
|
Mar 14, 2019 |
|
S.C. Monoclonal Antibodies
|
Mar 08, 2019 |
|
Lessons Learned (from the last week)
|
Feb 28, 2019 |
|
Axitinib's Big Weekend
|
Feb 21, 2019 |
|
IRIS
|
Feb 14, 2019 |
|
Cannabidiol (CBD) & Potential Drug Interactions In Cancer Patients
|
Feb 07, 2019 |
|
Mucositis & Stomatitis
|
Jan 31, 2019 |
|
Olaratumab, Goodbye?
|
Jan 24, 2019 |
|
Conversation With An Osteosarcoma Survivor
|
Jan 17, 2019 |
|
New & Niche Drugs
|
Jan 10, 2019 |
|
mFOLFIRINOX
|
Jan 03, 2019 |
|
Let's Talk About Mr. Gower
|
Dec 20, 2018 |
|
FOLFOX (MOSAIC Trial)
|
Dec 13, 2018 |
|
Gilteritinib
|
Dec 05, 2018 |
|
Elderly AML & Larotrectinib
|
Nov 27, 2018 |
|
Rise (& Fall) Of ESAs
|
Nov 21, 2018 |
|
Cyclophosphamide
|
Nov 15, 2018 |
|
Lorlatinib
|
Nov 06, 2018 |
|
October '18 Updates
|
Nov 01, 2018 |
|
Flu Vaccine Use with Immunotherapy
|
Oct 25, 2018 |
|
Talazoparib
|
Oct 18, 2018 |
|
P1: Tamoxifen for Breast Cancer Risk Reduction
|
Oct 11, 2018 |
|
Dacomitinib, cemiplimab & #oncopharm updates
|
Oct 04, 2018 |
|
Duvelisib
|
Sep 26, 2018 |
|
The Pseudomonas Exotoxin Drug
|
Sep 20, 2018 |
|
*Bonus Pod* World Marrow Donor Day '18
|
Sep 15, 2018 |
|
5-Fluorouracil
|
Sep 14, 2018 |
|
Ask OncoPharm (Part 1) & RELEVANCE
|
Sep 06, 2018 |
|
Influenza Vaccination during Chemo
|
Aug 30, 2018 |
|
Small Cell Lung Cancer: Established & Recent Advances
|
Aug 23, 2018 |
|
Mogamulizumab & August updates
|
Aug 16, 2018 |
|
Rituximab
|
Aug 09, 2018 |
|
Iobenguane I-131 & Lusutrombopag
|
Aug 02, 2018 |
|
Ivosidenib
|
Jul 26, 2018 |
|
A Brief History of Pemetrexed
|
Jul 20, 2018 |
|
Paclitaxel
|
Jul 11, 2018 |
|
Happy Fourth!
|
Jul 04, 2018 |
|
Encorafenib & Binimetinib
|
Jun 28, 2018 |
|
The Immunotherapy Two Step
|
Jun 21, 2018 |
|
Ondansetron Origins
|
Jun 13, 2018 |
|
Less is More & More
|
Jun 07, 2018 |
|
ASCO18 & Under the Radar Abstracts
|
May 31, 2018 |
|
Avatrombopag
|
May 25, 2018 |
|
PERSEPHONE: Bonus Pod
|
May 19, 2018 |
|
Cytarabine
|
May 18, 2018 |
|
Dual TKI Use & Frontline Dara
|
May 10, 2018 |
|
Methotrexate
|
May 04, 2018 |
|
AACR Update
|
Apr 19, 2018 |
|
NSABP-14
|
Apr 13, 2018 |
|
Vincristine
|
Apr 06, 2018 |
|
HOPA Highlights and Catching Up with NEJOncology
|
Mar 30, 2018 |
|
HOPA Preview
|
Mar 16, 2018 |
|
Landmark Testicular Cancer Study PVB (& BEP & EP)
|
Mar 09, 2018 |
|
Cycling thru the CDK Inhibitors
|
Mar 01, 2018 |
|
It's All Immunotherapy Nowadays
|
Feb 23, 2018 |
|
Apalutamide
|
Feb 15, 2018 |
|
Landmarks in Oncology Pharmacy: CMF
|
Feb 09, 2018 |
|
Foundations in Oncology Pharmacy: Doxorubicin
|
Feb 02, 2018 |
|
Updates in Oncology Pharmacy: Lu-177
|
Jan 26, 2018 |
|
Landmarks in Oncology Pharmacy: MOPP
|
Jan 19, 2018 |
|
Foundations in Oncology Pharmacy: Cisplatin
|
Jan 12, 2018 |
|
Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)
|
Jan 05, 2018 |
|
Landmarks in Oncology Pharmacy: Acute Leukemia in 1958
|
Jan 01, 2018 |
|
2017 Was A Good Year
|
Dec 18, 2017 |
|
Tales of Brave Iressa
|
Nov 30, 2017 |
|
Adjuvant TKIs?
|
Nov 17, 2017 |
|
Acalabrutinib
|
Nov 01, 2017 |